BREONICS Inc. functions as an organ regeneration research and discovery company that is developing a solution to the global shortage in kidneys available for transplant. The company's Exsanguinous Metabolic Support (EMS) technology enables the continued oxidative metabolism and function of organs and tissues while isolated from the rest of the human body. EMS is the first technology that can be used to intervene after cardiac arrest and repair ischemically damaged kidneys for transplantation. This unique ability of EMS changes todays limitation of recovering cadaveric kidneys from within minutes of death to a window of several hours postmortem. The aim is a significant broadening of the criteria for organ donation to include those patients who are declared dead from cardiac arrest at an accident scene, in the ER, or in the hospital.
